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Abstract 
The development of reverse genetics systems for the manipulation of viral and bacterial genomes 
has provided platforms for identifying virulence genes, studying pathogenesis and developing 
vaccines. Replication-competent vaccines (e.g., modified live virus (MLV) vaccines and 
replicating viral/bacterial vectors) are considered the most efficacious approach for vaccine 
development. We constructed replication-competent candidate vaccines for two viral diseases in 
pigs via reverse genetics. The first vaccine we designed is to protect against highly pathogenic 
porcine reproductive and respiratory syndrome virus (HP-PRRSV). HP-PRRSV can cause high 
mortality in pigs of all ages. Vaccines to protect pigs from HP-PRRSV are not commercially 
available in the US. According to previous studies, the non-structural protein (NSP) coding 
region of HP-PRRSV is closely related to the high mortality rate and the structural protein (SP) 
coding region contributes to the induction of broadly protective neutralizing antibodies. We 
created a chimeric PRRSV, of which the SP coding region was derived from HP-PRRSV and 
NSP coding region was derived from a low-pathogenic strain. This chimeric PRRSV caused 
similar CPE in cells as parental viruses, but had slower growth kinetics. We hypothesize that this 
chimeric virus will have a low pathogenicity and could serve as a candidate vaccine that can 
provide protection against HP-PRRV. The second vaccine vector is a modified Listeria innocua 
(L.inn), a non-pathogenic strain of Listeria. Genetically related Listeria monocytogenes (L.m) is a 
well-known intracellular pathogen that encodes specialized virulent determinants facilitating its 
intracellular growth and spread. Our goal is to make L.inn a vaccine vector that can deliver 
classical swine fever (CSF) viral antigen into intracellular environments by complementation of 
L.inn with selected L.m virulence genes necessary for intracellular survival and induction of a 
robust immune response. In this study, we constructed a shuttle vector pHT-E2 that can express 
  
CSFV antigen E2 in L.inn. We cloned the plcA-prfA operon of L.m virulence gene cluster (vgc) 
into pHT-E2, which enhanced the expression of E2 in L.inn. In future studies, we plan to clone 
additional L.m virulence genes into the shuttle vector to increase immunogenicity of this 
recombinant L.inn and test its ability to protect pigs from CSFV.
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Chapter 1 - Use of reverse genetics to create an attenuated HP-
PRRSV strain 
Abstract: Porcine reproductive and respiratory syndrome (PRRS) is the most economically 
important disease of pigs worldwide, for which current vaccines provide limited protection due 
to the high genetic diversity and rapid mutation of circulating PRRSV strains.  In 2006, highly 
pathogenic PPRS (HP-PRRS) characterized by high fever (>41°C) and high morbidity and 
mortality in pigs of all ages emerged in China and devastated the pig industry. Application of 
MLV vaccines based on an attenuated HP-PRRSV strain have been reported in China, but no 
commercial HP-PRRSV vaccine is available in the U.S.. The aim of this study is to use reverse 
genetics to recreate and attenuate HP-PRRS virus. Using the infectious clone of a low-
pathogenic (LP) classical NA strain P129 as a backbone, we constructed a full-length HP-
PRRSV clone JXA1 and a series of P129/JXA1 (LP/HP) chimeric clones. Interestingly, neither 
JXA1 nor P129/JXA1 chimeric clones could produce infectious virus in MARC-145 cells, 
possibly due to the existence of fatal mutations in the original JXA1 sequence; however, we 
managed to use the sequence of a third virus, HP-PRRSV HV strain, to restore infectivity and 
generated an infectious P129/JXA1/HV triple chimeric clone. The virus rescued from this triple 
chimeric clone caused similar CPE in cells as parental viruses, but had slower growth kinetics. 
The viral genome contains NSP coding region derived from P129 and SP coding region from 
HP-PRRSV. According to previous studies, the non-structural protein (NSP) coding region of 
HP-PRRSV is closely related to the high mortality rate and the structural protein (SP) coding 
region contributes to the induction of broadly protective neutralizing antibodies. We hypothesize 
that this P129/JXA1/HV chimeric clone will have a low pathogenicity but could serve as a 
candidate vaccine that can provide protection against both HP-PRRV and classical PRRSV. 
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1.1  Introduction 
Porcine reproductive and respiratory syndrome (PRRS), characterized by respiratory problems, 
weight loss and poor growth performance, as well as reproductive failure in sows [1, 2] was first 
reported in North America in 1987 [3] and in Europe in 1990. To date, PRRS has become an 
endemic disease in almost all pork-producing areas of the world and has led to huge economic 
losses in the pork industry. A recent study shows that this economically important disease costs 
the U.S. pork industry $664 million annually,  an increase from the $560 million estimated 
annual cost in 2005 [4]. 
Porcine reproductive and respiratory syndrome virus (PRRSV), the causative agent of PRRS, 
was first isolated in the Netherlands in 1991 [5] and in the USA in 1992 [6]. PRRSV is an 
enveloped, positive-strand RNA virus which, together with lactate dehydrogenase-elevating 
virus of mice (LDEV), equine arteritis virus (EAV), and simian hemorrhagic fever virus (SHFV), 
belongs to the family Arteriviridae within the order Nidovirales [7, 8]. Phylogenetic analysis 
divided PRRSV isolates into two distinct major genotypes: Type I (European) represented by 
Lelystad strain, and Type II (North American) with VR2332 as the prototype strain [9]. These 
two genotypes differ antigenically as well as genetically and only share an approximately 60% 
overall sequence identity [10, 11]. The PRRSV genome is approximately 15 kb and includes the 
5’ cap structure and 3’ polyadenylated tail. The genome contains at least 10 overlapping open 
reading frames (ORFs) [12, 13]. The ORF1a and ORF1b, constituting 75% of the viral genome, 
are translated directly from the incoming genomic RNA into two large polyproteins pp1a and 
pp1ab and then autoproteolytically cleaved into at least 15 nonstructural proteins (NSPs) [14-16]. 
The NSPs participate in genome replication and subgenome transcription [17]. The viral 
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structural proteins are encoded by ORFs 2 to 7, locating downstream of ORFs 1a and 1b, which 
are involved in virus infectivity and neutralizing antibody elicitation [18-20].  
Vaccination is currently the principal strategy for prevention the treatment of PRRSV [21, 22]. 
PRRSV neutralizing antibodies induced by vaccination are believed to prevent infection and 
transplacental infection of pregnant sows [23]. There are two types of PRRS vaccine that are 
commercially available, modified-live virus (MLV) vaccine and killed virus (KV) vaccine. 
PRRS MLV vaccines licensed for use in the US are derived from the North American (NA) 
PRRSV, which include Ingelvac PRRS MLV and ReproCyc PRRS-PLE (both from VR-2332; 
Boehringer Ingelheim), Ingelvac PRRS ATP (from JA142; Boehringer Ingelheim), and Fostera 
PRRS (from P129; Zoetis) [24-26]. PRRS KV vaccine is licensed for use in European countries 
and other parts of the world, but not in the US. PRRS MLV vaccine has been proved to be 
effective for its protection against genetically homologous PRRSV strains, but only partial 
protective against heterologous strains, which is due to the high genetic diversity and rapid 
mutation of circulating PRRSV strains [27].  PRRS KV vaccine only confers limited protection 
against either homologous or heterologous strains. Hence, a better PRRSV vaccine effective in 
providing protection against both homologous and heterologous PRRSV strains is still needed. 
In 2006, atypical PRRS outbreaks were reported in China with the characteristics of high fever 
and high morbidity and mortality in pigs of all ages [8, 28].  The causative agent was identified 
as highly pathogenic PRRS virus (HP-PRRSV). Different from classical PRRSV strains, HP-
PRRSV can induce neurological symptoms (e.g., shivering), prolonged high fever of above 
41°C, and red discoloration of the ears and body; it has a morbidity of  50–100% and the highest 
mortality rate can reach 100% in nursery pigs [8, 28]. Complete genome sequencing and 
phylogenetic analysis demonstrated that Chinese HP-PRRSV is a newly emerged evolutionary 
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subgroup that belongs to type II genotype but has a unique molecular hallmark of a 
discontinuous deletion of 30 amino acids in the NSP2 coding region [8, 28, 29].  At first, this 
deletion was considered related to the high virulence of HP-PRRSV, but later study disproved 
this theory [30]. Until now, the location of virulence determining region in the HP-PRRSV 
genome still remains unknown. In a recent study, researchers exchanged different ORFs between 
a HP strain JXwn and classical NA train HB-1. Pathogenicity analyses showed that JXwn 
ORF1b region, but not the structural protein region, could confer fatal virulence to HB-1, 
suggesting that replicase genes play an important role in virulence of HP-PRRSV [31]. 
Currently used NA strain based MLV vaccines for classical PRRS have limited protection 
against HP-PRRSV infection [32, 33]. Application of MLV based on attenuated HP-PRRSV 
strains (JXA1-R, HuN4-F112 and TJM) have been reported in China and showed effective 
protection against challenge with wild-types HP viruses [33, 34]. According to vaccine efficacy 
studies conducted in our lab, JXA1-R can also protect pigs from challenge with current 
circulating North American PRRSV strain NADC-20 by inducing high titer of neutralizing 
antibodies to NADC-20 (unpublished data). However, there is no commercial HP-PRRSV 
vaccine available in the US. Although HP-PRRSV only exists in Asia at the present time, it may 
become a threat to the US swine industry in the future as the result of the increasing international 
transportation.  This availability of a HP-PRRSV vaccine is of great importance in protecting the 
US swine industry from the devastating attack of HP-PRRSV. 
Reverse genetics, in the opposite direction of classical genetics, is an approach to discover what 
phenotypes arise as a result of particular genetic sequences. It can be a powerful tool in 
analyzing the fatal virulent determinant of HP-PRRSV and seeking ways to effectively 
attenuation for MLV vaccine development. The aim of this study is to use reverse genetics to 
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recreate and attenuate HP-PRRS virus. Using the infectious clone of a low-pathogenic (LP) 
classical NA strain P129 as a backbone, we constructed a full-length HP-PRRSV clone JXA1 
and a series of P129/JXA1 (LP/HP) chimeric clones. Interestingly, neither JXA1 nor P129/JXA1 
chimeric clones could produce infectious virus in MARC-145 cells, possibly due to the existence 
of fatal mutations in the original JXA1 sequence; however, we managed to use the sequence of a 
third virus, HP-PRRSV HV strain, to restore infectivity and generated an infectious 
P129/JXA1/HV triple chimeric clone. The recombinant virus rescued from this triple chimeric 
clone contains NSP coding region derived from P129 and SP coding region from HP-PRRSV. 
According to previous studies, the non-structural protein (NSP) coding region of HP-PRRSV is 
closely related to the high mortality rate and the structural protein (SP) coding region contributes 
to the induction of broadly protective neutralizing antibodies. We hypothesize that this 
P129/JXA1/HV chimeric clone will have a low pathogenicity but could serve as a candidate 
vaccine that can provide protection against both HP-PRRV and classical PRRSV. 
1.2  Materials and Methods 
1.2.1 Cells and virus 
MARC-145 cells were grown in Modified Eagle’s medium (MEM, Gibco) containing 10% fetal 
bovine serum (FBS), penicillin (100 U /ml) and streptomycin (100 μg /ml). Cells were 
maintained at 37°C with 5% CO2. For viral titration, MEM containing 2% FBS, penicillin (100 
U/ml) and streptomycin (100 μg/ml) was used. The full-length infectious cDNA clone plasmid 
(pCMV-P129, pcDNA-HV) of PRRSV P129 (GenBank: AF494042) and of HP-PRRSV HV 
(GenBank: JX317648) used in this study have been previously described [35, 36]. pcDNA-HV 
was a kind gift from Dr. Wen-hai Feng (State Key Laboratory of Agro-biotechnology, China 
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Agricultural University, Beijing, China). pCMV-P129 was a kind gift from Dr. Bob Rowland 
(College of Veterinary Medicine, Kansas State University, US).  
1.2.2 Construction of JXA1 and chimeric full-length cDNA clones 
pCMV-P129 infectious clone was used as the backbone for the construction of new infectious 
clones. Six restriction enzymes, PacI, MluI, PmeI, BspDI, AfeI, BsrGI and SpeI in the pCMV-
P129 infectious clone were selected for replacing the P129 genome with corresponding 
sequences from HP-PRRSV. Five corresponding DNA fragments, PM (PacI-MluI), MP (MluI-
PmeI), PA (PmeI-AfeI), AB (AfeI-BsrGI) and BS (BsrGI-SpeI), were synthesized (GenScript) 
based on the sequence of JXA1 strain of HP-PRRSV (GenBank: EF112445). These five 
fragments cover the whole JXA1 genome and represent 1-3150 (PM), 3145-7605 (MP), 7597-
11714 (PA), 11709-12623 (AB) and 12618-15341 (BS) of the genome respectively. MluI, AfeI, 
BsrGI enzyme sites were created by mutating the nucleic acid sequence of the JXA1 genome 
without any change in amino acid sequence. PA fragment was further digested by BspDI site to 2 
parts (PmeI-BspDI and BspDI -AfeI). The six fragments were cloned via corresponding enzyme 
sites in the pCMV-P129 to create a full-length JXA1 and series of P129/JXA1chimeric clones.  
BS fragment corresponding region in HP-PRRSV HV infectious clone was amplified by PCR 
using primers HV-BS-F: AGCTTCATGACTTTCAGCAATGG and HV-BS-R: 
gaacACTAGTTAGAAGGCACAGTCGAGG (SpeI site is underlined). After double-digestion 
with BsrGI and SpeI, HV BS fragment was purified with QIAquick Gel Extraction Kit (Qiagen) 
and cloned into BsrGI-SpeI sites in JXA1 and P129-JS to create JXA1-HBS and P129-JAB-HBS 
respectively. 
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The correctness of the exchanged regions in all full-length clones was verified by PCR with 
specific primers. The whole viral genome and 5’ and 3’ vector sequences in P129-JAB-HBS 
clones were sequenced to ensure no mutations exist.  
1.2.3 Site-directed mutagenesis 
An 11712 G deletion mutation in AfeI enzyme site was identified in JXA1 full-length clone by 
sequencing. 11712G deletion was added to the genome by Q5 Site-Directed Mutagenesis Kit 
(NEB) using JXA1-NEB-F: gCTTACCATGGTGAAATGC and JXA1-NEB-R: 
GCTAGACAGAATAATTTTGGC (AfeI site is underlined). Reverse mutant was identified by 
the recovery of the AfeI site.  After site-directed mutagenesis, JXA1 full-length clone was 
sequenced to ensure no more mutations existed. 
1.2.4 Recovery of viruses from full-length cDNA clones 
All full-length cDNA clone plasmids were purified with EndoFree Plasmid Maxi Kit (Qiagen) 
and transfected with 90% confluent MARC-145 cells using Lipofectamine 2000 (Life sciences). 
MARC-145 cells were maintained in 10% MEM medium in 6-well plates. Cells were washed 
with PBS once and 750 μl Opti-MEM (Gibco) was added to each well immediately before 
transfection. Transfection was conducted according to the protocol supplied by the manufacturer 
(Life sciences). Transfection mixtures were removed after 4-6 hours incubation and 10% MEM 
was added to cells. Cells were observed daily after transfection for morphological observation 
and cytopathic effects (CPE). The culture supernatants were harvested at 4 days post-
transfection, no matter whether CPE were observed or not. Two cycles of freeze-thaw were 
performed and cells were centrifuged for 5 min at 1200 rpm. Supernatants were collected and 
designated P1 (passage 1). P1 supernatants were added to 90% confluent MARC-145 cells in 2% 
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MEM in 1/50 volume of the cell culture. Cells were incubated for an additional 48 to 72 hours to 
allow the possible CPE formation. Supernatants were harvested in the same way as for P1 and 
designated P2.  P3 were prepared in the same way as for P2. Each passage was aliquoted and 
stored at -80°C until use.   
1.2.5. Titration of rescued viruses  
The titers of rescued P129 (P3 virus) and Hybrid PRRSV (P3 virus) were determined using a 
microtitration infectivity assay and expressed as 50% tissue culture infective dose per ml 
(TCID50/ml). Virus stocks were 10-fold serially diluted (10
-1
 to 10
-8
) in MEM containing 2% 
FBS and incubated with 90% confluent monolayers of MARC-145 cells cultured in 96-well 
plates. Eight replicate wells were prepared for each dilution. After incubation for 48 to 72 h at 
37°C, the virus titers were determined.  
1.2.6 RNA extraction, RT-PCR and sequencing 
Viral RNA of hybrid PRRSV was extracted using P3 virus stock using Viral Nucleic Acid 
Extraction Kit II (IBI scientific). First-strand cDNA synthesis was performed by ProtoScript II 
First Strand cDNA Synthesis Kit (NEB) using reverse primers PRRSVpart1-R: 
TTTGCCAGTTTTCTCGCACG and PRRSVpart2-R: AATTACGGCCGCATGGTTCT 
according to the standard protocol supplied by the manufacturer. The viral genome was 
amplified in 4 fragments by Q5 High-Fidelity DNA Polymerase (NEB) using primer pairs 
PRRSVpart1-F+Hybrid1a-R, Hybrid1b-F+Hybrid1b-R, PRRSVpart2-F+PRRSVpart2-R and 
PRRSVpart2-F+Hybrid2b-R (Table 1.1). Amplified products were purified using the PCR 
Purification Kit (Qiagen) and sequenced.   
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1.2.7 Bioinformatics analysis 
Sequence alignments between ORFs in JXA1 BS and HV BS were conducted using NCBI 
Protein Blast. A phylogenetic tree of 10 different PRRSV strains was constructed based on 
complete genomes obtained from GenBank. Multiplex sequence alignments were generated by 
CLUSTAL X (version 2.1) [37]. Phylogenetic analysis was conducted using the MEGA software 
(version 4.0.2). Structure homology-modeling was conducted by SWISS-MODEL with 
automatic template search. SMTL ID of templates used for homology-modeling of GP4 
ectodomain were 2q22.1.A and 4cmr.1.A. SignalP 4.1 and PredictProtein were used for 
prediction of potential signal peptide and transmembrane helices repetitively. 
1.3  Results 
1.3.1 Construction of full-length JXA1 and P129/JXA1 chimeric clones 
JXA1 is the first HP-PRRSV isolate discovered in 2006 [8] and also serves as the reference 
strain of HP-PRRSV. PRRSV P129 is a lowpathogenic NA strain, originally isolated in the 
autumn of 1995 from a swine herd in southern Indiana [38]. P129 only shares 92% genome 
similarity with JXA1and pCMV-P129 is a full-length infectious clone of P129 (Fig. 1.1). The 
P129 genome in pCMV-P129 was replaced by JXA1 genome fragments, PM, MP, PA, AB and 
BS by unique enzyme sites in P129 genome (Fig. 1.2A). A full-length JXA1 clone and a series of 
P129/JXA1 chimeric clones were created (Fig. 1.2B). P129-JS contains 5’ UTR and non-
structural protein encoding region from P129 and structural protein encoding region (SP) and 3’ 
UTR (AB+BS) from JXA1. JXA-P1b contains 5’ UTR, ORF1a and SP from JXA1 and ORF1b 
of P129.  P129-JAB contains only the AB fragment from JXA1 with the rest of the sequence 
coming from the P129 genome. JXA1 clone is consisted of entire and only JXA1 genome. A 
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deletion mutation of 11712 G in AfeI enzyme site in JXA1 clone was identified after PA 
fragment was inserted. Site-Directed Mutagenesis was used to add this 11712 G back to the 
genome and recovered the AfeI enzyme site. The entire viral genome and the 5’ and 3’ junction 
region in vector in JXA1 clone were sequenced. The first nucleotide ‘A’ of the viral genome 
positioned behind the -25 TATA box of CMV promoter and unique PacI enzyme site (Fig. 1.2C) 
and the genome ends with 21-residue polyadenosine tail.  
1.3.2 Infectivity of the full-length JXA1 and P129/JXA1 chimeric clones in cell 
culture 
Infectivity of full-length JXA1 and P129/JXA1 chimeric clones was determined in MARC-145 
cells. MARC-145 cells were directly transfected with the same amount of plasmid DNA of 
JXA1, JXA-P1b, P129-JS, P129-JAB or P129 respectively. CPE appeared at 3 days post-
transfection for P129-JAB and P129 (Fig. 1.3). CPE was not observed for other full-length 
clones. The culture supernatants of all transfected cells were collected at 4 days post-transfection 
no matter whether CPE appeared or not and designated P1 (passage 1). To examine whether the 
absence of visible CPE in cells transfected with JXA1, JXA-P1b and P129-JS was due to low 
and therefore undetectable levels of virus production and stability of infectivity of viruses 
rescued from P129-JAB clone, P1 supernatants were passaged two times in MARC-145 cells for 
infectivity amplification. No CPE was observed for all JXA1, JXA-P1b and P129-JS even in P3, 
while extensive CPE was evident in 2 days in cells infected with the P1 and P2 P129-JAB or 
P129 viruses. These results suggested lethal mutation(s) may exist in the genome of JXA1 and 
most likely were located in the BS fragment. As a consequence, no viable virus was generated 
from cells transfected with any clones that had the JXA1 BS region.  
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1.3.3 Construction of JXA1/HV and P129/JXA1/HV chimeric clones 
To further analyze if there was lethal mutation(s) in BS fragment, the homologous region of BS 
in the infectious clone of another Chinese HP-PRRSV strain HV was cloned and used to replace 
the BS in JXA1 clone and P129-JS clone. Two new chimeric clones JXA1-HBS and P129-JAB-
HBS were generated (Fig. 1.4A). HV strain shares an overall sequence identity of 99.3% with 
JXA1 (Fig. 1.1). HV BS also shares an identity of 99.4% in nucleotide sequence with JXA1 BS. 
MARC-145 cells were transfected with the same amount of plasmid of JXA1-HBS P129-JAB-
HBS, HV or P129 respectively. CPE was observed at 3 days post-transfection (Fig. 1.5) for 
P129-JAB-HBS, HV and P129. No CPE was observed for JXA1-HBS. Supernatant were 
collected at day 4 and passaged 2 more times in MARC-145 cells. The titer of ‘Passgae-3’ virus 
was 5.62 × 10
5
 TCID50/ml for P129-JAB-HBS and 1.78 ×10
7
 TCID50/ml for P129, indicating 
that the P129/JXA1/HV chimeric virus has slower growth kinetics compared to parental P129 
virus. The plague morphology of progeny virus of P129-JAB-HBS was indistinguishable 
compared to the parental P129 virus (Fig. 1.5). No CPE appeared in any passage of JXA1-HBS. 
This result supports our hypothesis that fatal mutation(s) was harbored in JXA1 BS region, but 
also indicated that there are more fatal mutations existing in the remaining part of the JXA1 
genome. 
To rule out the possibility of contamination with parental viruses in P129-JAB-HBS samples, 
viral RNA was extracted from P129-JAB-HBS P3 virus and RT-PCR and sequencing of the 
whole viral genome were performed. Sequence of AB fragment and BS fragment of the virus 
derived from the infectious clone P129-JAB-HBS are the same as the AB of JXA1and BS of HV 
respectively. AB fragment derived from JXA1 contains most of the ORF2a and the intact 
ORF2b. BS fragment of HV contains the intact ORF3, ORF4, ORF5, ORF6, ORF7 and 3’UTR 
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and partial ORF2 (Fig. 1.4B).The rest of the non-structural proteins encoding region and 3’ UTR 
are identical with P129. The pCMV-P129 infectious clone contains a silent mutation C to T at 
nucleotide position 1559 of the genome that is a genetic marker distinguishing the infectious 
clone from wild type P129. The P129-JAB-HBS also retained this 1559T in its genome.  
1.3.4 Molecular analysis of JXA1 BS and HV BS 
To further analyze the location of possible fatal mutations in JXA1 BS region, sequence 
alignment was conducted between JXA1 BS and HV BS region for all ORFs (protein blast) and 
3’ terminal untranslated region (nucleotide blast). Eight amino acid differences between these 2 
strains in the BS region were identified (Fig. 1.6). No nucleotide differences were found in 3’ 
UTR between these two strains. Two amino acid differences (F12L and F248V) distribute in 
GP3, 5 locate in GP4 (I66S, S132T, L172F, P173A and S174I) and 1(L196Q) was in GP5. 
Among them, F12L in GP3 locates in the predicted signal peptide region, I66S and S132T in 
GP4 locate in the predicted ectodomain, L172F, P173A and S174I in GP4 are predicted within 
transmembrane region, and F248V in GP3 and L196Q in GP5 are predicted being in C-terminal 
endodomain [18]. To analyze the possible effect of F12L mutation in GP3, prediction (SignalP) 
was conducted for signal peptide region in JXA1 GP3 and HV GP3, but no difference was found 
between these two proteins (data not shown). Structure homology-modeling (SWISS-MODEL 
Workspace) was conducted for ectodomain of JXA1 GP4 and HV GP4. No obvious difference in 
tertiary structure was found in I66S and S132T location in GP4 (Fig. 1.7). Structure homology-
modeling could not be conducted for the transmembrane region of GP4 or endodomain of GP3 
or GP5, because no templates were found matching the target regions. 172-174 LPS are within 
the alpha-helix structure of HV GP4 transmembrane region. If the change from LPS to FAI in 
JXA1 GP4 disturbed the helix structure, it may influence the anchor of JXA1 GP4 in the 
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membrane. However, analysis of transmembrane region using PredictProtein did not show any 
difference in the length of the helical transmembrane region in JXA1 and HV GP4. PRRSV GP5 
has a large C-terminal endodomain, around 71 aa, and GP3 also has a 54 aa predicted 
endodomain. Both endodomain were predicted as disordered region in solution with no 
significant secondary structure (PredictProtein).  There are no studies showing that these two 
proteins have any interaction with other intracellular proteins [18]. Therefore, it is difficult to 
predict that if the mutations in the endodomain (F248V in GP3 and L196Q in GP5) can affect the 
function of these two proteins. Interestingly, in a comparative genomic analysis of a HP-PRRSV 
strain, HBR, at the different passage levels, the same F248V mutation in GP3 and I66S mutation 
in GP4 were found in the 125
th
 passage (F125) [39]. Therefore, these 2 mutations are less likely 
the cause of the loss of infectivity.   
1.4  Discussion 
Conventional approaches to live-attenuation virus vaccine development through passaging 
(forward genetics) or inactivation, though highly successful in the past, has been shown to be  
inefficient for generating broadly protective PRRSV vaccine and understanding PRRSV 
pathogenesis and attenuation mechanism. Reverse genetics, in the opposite direction of classical 
genetics, is an approach to discover what phenotypes arise as a result of particular genetic 
sequences. It allows introduction of changes at specific sites or regions of the viral genome in 
order to create modified infectious viruses [40], which can be a powerful tool for analyzing the 
fatal virulent determinant of HP-PRRSV and seeking ways to effective attenuation and 
developing MLV vaccines with expected characteristics (e.g., broad protection). Aimed at 
developing a reverse genetics system for studing of HP-PRRSV virulence and attenuation 
mechanism, we created a full-length HP-PRRSV clone and a series of full-length LP/HP PRRSV 
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chimeric clones. The full length cDNA clone of HP-PRRSV was generated by replacing all the 
viral genome in pCMV-P129 with sequence of JXA1 strain published in NCBI. Unfortunately, 
no virus with infectivity was rescued from this full-length clone. Fragments of JXA1 were 
synthesized according to the GenBank record EF112445.  Although sequencing of the genome 
was modified to create MluI, AfeI, BsrGI enzyme sites, amino acid sequences of ORFs were not 
altered. Sequencing of the genome also showed that no mutations were introduced during the 
cloning procedure. Moreover, in all full-length JXA1/P129 chimeric clones created in this study, 
including JXA1-P1b, P129-JS and P129-JAB, only P129-JAB can produce progeny infectious 
virus. These data suggested that fatal mutation(s) may exist in the original JXA1 sequence in the 
GenBank record EF112445, and the BS fragment is the most likely region that harbors the 
mutation(s). To test this hypothesis, the BS region from another HP-PRRSV infectious clone 
pcDNA-HV was amplified by PCR and then cloned into the JXA1 and P129-JS to replace the 
JXA1 BS region. The new chimeric clones were named JXA1-HBS and P129-JAB-HBS. 
Significant CPE could be observed after 3 days post transfection of MARC-145 cells with P129-
JAB-HBS and stably showed up in every further passage. However no CPE was observed in 
MARC-145 cells transfected with JXA1-HBS. The genome of P129-JAB-HBS derived 
recombinant viruses were extracted and sequenced to ensure no contamination with other viral 
strains. 
The finding that replacement with HV BS region renders P129-JAB-HBS, but not JXA1-HBS, 
infectious supports our hypothesis that fatal mutation(s) was harbored in JXA1 BS region, and 
also indicated that there are more fatal mutations existing in the rest of the JXA1 genome. 
Sequence alignment between all ORFs locating in JXA1 BS and HV BS region indicated eight 
amino acid substitutions between these 2 strains, two of them in GP3, five in GP4 and one in 
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GP5 with a diverse distribution, covering the predicted signal peptide region, ectodomain, 
transmembrane region and endodomain (Fig. 1.6). To analyze the potential effect of these 
mutations in protein function, comparisons were conducted in secondary and tertiary structure 
level using different predict services. Prediction at the secondary structure level (SignalP and 
PredictProtein) did not show any mutations cause obvious difference in potential signal peptide 
and transmembrane region. Since no direct structure information is available for none of these 3 
proteins, homology-modeling (SWISS-MODEL) was conducted for tertiary structure prediction. 
However, homology templates that can match the target regions were only found for the 
extracelluer region of GP4 and tertiary structure modeling did not show any difference in 
mutation region between JXA1 GP4 and HV GP4 either. There is not significant secondary 
structure predicted in endodomain in GP3 and GP5, of which the function still remain unknown. 
Therefore, the effect of mutations in endodomain could not be predicted. As the bioinformatics 
analysis was not conclusive in this study, site-directed mutagenesis may be used in the further 
studies for screening the fatal mutation(s) in JXA1 BS fragment.  
The P129/JXA1/HV triple chimeric clones, P129-JAB-HBS, created in this study has structural 
protein coding region derived from HP-PRRSV and non-structural protein encoding region from 
a low pathogenic strain. This characteristic can be very useful in HP-PRRSV vaccine 
development and the study of pathogenicity of HP-PRRSV. First, structural protein contains the 
most neutralizing epitopes that are found in PRRSV; GP5 harbors the major neutralizing 
epitopes and GP2, GP3 and GP4 contain minor neutralizing epitopes[24]. Therefore, structural 
protein coding region of HP-PRRSV in P129-JAB-HBS may be able to induce effective humoral 
immunity against HP-PPRSV in pigs. Secondly, according to a vaccine efficacy study conducted 
in out lab, HP-PRRSV MLV vaccine can protect pigs from the challenge of heterologous North 
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American strain NADC-20 by inducing high titer of neutralizing antibodies to NADC-20 
(unpublished data). These data suggest that neutralizing antibodies induced by HP-PRRSV can 
be broadly protective for heterologous challenge, and P129-JAB-HBS may preserve this 
characteristic in its SP coding region. Moreover, since P129-JAB-HBS only partially contains 
the HP-PRRSV genome, it can have an attenuated pathogenicity compared to the parental virus. 
It remains controversial as to which region(s) in the viral genome is the fatal virulence 
determinant; however recent studies [31, 41, 42] suggested non-structural proteins contribute 
more of the virulence of HP-PRRSV than structural proteins. Further study of the pathogenicity 
and immunogenicity of P129-JAB-HBS can provide new insights on the mechanism of virulence 
determination in PRRSV and on new PRRS vaccine development.  
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1.5  Figures and Tables 
  
Figure 1.1 Phylogenetic relationship of PRRSVs. Phylogenetic tree based on complete 
genome demonstrated that Chinese HP-PRRSV is a new evolutionary subgroup in Type II North 
American genotype. VR-2332, prototype strain of Type II PRRSV; P129, JA142 (GenBank: 
AY424271) and NVSL97-7895 (GenBank: AY545985) are endemic strains in the US; CH1-a 
(GenBank: AY032626), HB-1 (GenBank: AY150312) and HB-2 (GenBank: AY262352) are 
classical PRRSV Chinese isolates. HV, TJ (GenBank: EU860248), JXA1 and HuN4 (GenBank: 
EF635006) are Chinese HP-PRRSV isolates. 
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Figure 1.2 Strategies for construction of the full-length genomic cDNA clone of JXA1 and 
P129/JXA1 chimeric clones. (A) JXA1 genome was synthesized as five large DNA fragments 
with unique enzyme sites on the both ends. P129 genome in pCMV-P129 was replace by these 
five fragments one by one using corresponding enzyme sites. PA fragment was divided to 2 parts 
by BspDI for cloning due to the low ligation efficiency for long fragment. (B) Four new full-
length genomic cDNA clones were created.  JXA1 clone contain the entire and JXA1 genome; 
A 
B 
C 
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JXA1-P1b is consisted of JXA1 sequence except the ORF1b that is derived from P129; P129-JS 
contains structural protein (SP) coding region and 3’ UTR from JXA1, and 5’ UTR and non-
structural protein coding region from P129; P129-JAB contains only AB fragment from JXA1 
and rest sequence are P129 genome. (C) Nucleotide sequence of the region between the human 
cytomegalovirus (CMV) immediate early promoter and the 5’ terminal of the viral genome in 
JXA1 full-length clone. TATA box from the CMV promoter and the start of the JXA1 genome is 
underlined in bold face. The restriction sites are underlined. 
 
Figure 1.3 Transfection of full-length JXA1 and P129/JXA1 chimeric clones with MARC-
145 cells. MARC-145 cells in a 6-well culture plate were transfected with (A) PBS or purified 
plasmid of (B) JXA1, (C) P129 or (D) P129-AB using Lipofectamine 2000 according to the 
protocol supplied by the manufacturer (Life Sciences). Cells were photographed at 3 days post-
transfection. Cytopathic effect was visible for cells transfected with P129-AB or P129, but not 
for JXA1 or PBS control. 
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Figure 1.4 Construction of the JXA1/HV and P129/JXA1/HV chimeric clones. Homologous 
region of JXA1 BS in another Chinese HP-PRRSV strain HV was amplified by PCR and cloned 
into the BsrGI and SpeI sites in JXA1 and P129-JS clones. (A) Two new chimeric clones JXA1-
HBS and P129-JAB-HBS were generated. P129-JAB-HBS is a triple chimeric clone, containing 
the structural protein coding region derived from HP-PRRSV and non-structural protein coding 
region of P129. (B) AB fragment contains most of the ORF2a and the intact ORF2b. BS 
fragment contains the intact ORF3, ORF4, ORF5, ORF6, ORF7 and 3’UTR and partially ORF2. 
 
A 
B 
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Figure 1.5 Transfection of JXA1-HBS and P129-JAB-HBS chimeric clones with MARC-
145 cells. MARC-145 cells in a 6-well culture plate were transfected with (A) PBS or (B) 
purified plasmid of HV, (C) P129, (D) P129-JAB-HBS or (E) JXA1-HBS (E) using 
Lipofectamine 2000 according to the protocol supplied by the manufacturer (Life Sciences). 
22 
Cells were photographed at 4 days post-transfection. Cytopathic effect was significant for cells 
transfected with HV, P129 or P129-JAB-HBS, but not for JXA1-HBS or PBS control. 
 
 
Figure 1.6 Differences in protein sequence between JXA1 BS and HV BS. HV BS has 8 
amino acids differences that distribute in ORF3, ORF4 and ORF5 compared to JXA1 BS. Amino 
acids in BS fragment of JXA1are in green and amino acids in BS fragment of HV strain are in 
orange. Among them, F12L in GP3 locates in predicted signal peptide (SP) region, I66S and 
S132T in GP4 locate in predicted ectodomain, L172F, P173A and S174I in GP4 are predicted 
within transmembrane (TM) region, and F248V in GP3 and L196Q in GP5 are predicted being in 
C-terminal endodomain [18].  
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Figure 1.7 Structure homology-modeling for BS fragments of JXA1 and HV strains. 
Structure homology-modeling (SWISS-MODEL, automatically template search) was conducted 
for regions in JXA1 GP4 containing (A) 66I and (B) 132S and regions in HV GP4 that contains 
(C) 66S and (D) 132T in GP4. Structure of amino acids that differ in JXA1 GP4 and HV GP4 
were indicated in the predicted model by back arrows. 
Table 1.1 Primers used in RT-PCR for amplifying the genome of P129-JAB-HBS chimeric 
virus. 
No. Name Sequence 
1 PRRSVpart1-F TGACGTATAGGTGTTGGCTCT 
2 Hybrid1a-R CCTGCACTCGGGATCAACTT 
3 Hybrid1b-F TCGGTTTCGTTCCCCTCTTG 
4 Hybrid1b-R CTCAGGGTTGCCCCTAACAG 
5 PRRSVpart2-F GGGATGGGGACCGTTTGAAT 
6 PRRSVpart2-R AATTACGGCCGCATGGTTCT 
7 Hybrid2b-R AAAGCGGGCATACCGTGTAA 
A B 
C D 
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Chapter 2 - Construction of a recombinant Listeria innocua vaccine 
vector for the expression of a CSF viral antigen 
Abstract: The use of bacterial vectors for the development of next-generation viral vaccines has 
proved beneficial in many studies. L. monocytogenes (L.m) is a well-known intracellular 
pathogen that encodes specialized virulent determinants to facilitate its intracellular growth and 
spread. It has been widely used as an experimental vaccine vector, given its capability to 
stimulate cell-mediated immunity. However, the safety of live L.m vector remains an important 
issue which limited its development in clinical applications. L. innocua (L.inn) is a non-
pathogenic strain in the Listeria genus, closely related to L. monocytogenes (L.m). Our goal is to 
make L.inn a vaccine vector that can deliver target viral antigen into intracellular environments 
by complementation of L.inn with selected L.m virulence genes necessary for intracellular 
survival and induction of a robust immune response. In this study, we constructed a shuttle 
vector pHT-E2 that can express classical swine fever (CSF) viral antigen E2 in L.inn. At the 
same time, we cloned the plcA-prfA operon of L.m virulence gene cluster (vgc) into the pHT-E2. 
The presence of this operon enhanced the expression of E2 in L.inn. In future studies, we plan to 
clone additional L.m virulence genes into the shuttle vector to increase immunogenicity of this 
recombinant L.inn and test its ability to protect pigs from CSFV.   
2.1 Introduction 
Currently, vaccines developed to protect against viral pathogens fall into three major classes 1) 
modified live virus (MLV) vaccines [22, 43, 44] 2) antigen delivery systems based on replicating 
viral/bacterial vector [45], and 3) vaccines developed using non-replicating strategies like 
inactivated virus, subunit vaccines and nucleic acid vaccines [44, 46]. Although MLV vaccines 
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are highly efficacious, they are associated with potential risk for reversion to virulence [47]. 
Vaccines that are not based on replication-competent materials are considered to be safer, but 
they usually require a strong adjuvant, which can often induce detrimental tissue reactions, or 
require repeat injections [44, 48]. Bacterial vectors permit targeted delivery of viral antigens to 
mammalian cells or tissues in a way that closely mimics a natural infection to effectively 
stimulate the immune system [49, 50]. Therefore, bacterial vectors provide a vaccine technology 
for the development of next-generation viral vaccines. Over the past 15 years, experimental 
bacteria vectors based on Bacille Calmette-Guerin (BCG), Listeria monocytogenes, Salmonellae 
and Shigellae have been developed and tested in animal models [45, 49]. The ability of L.m to 
induce major histocompatibility complex (MHC) class I-restricted CD8
+
 T-cell responses makes 
it an attractive option for a viral vector [51, 52]. 
Listeria monocytogenes (L.m) is a gram-positive, food-borne opportunistic intracellular human 
and animal pathogen. It causes the disease listeriosis, which culminates in a gastroenteritic 
infection in healthy adults but can lead to serious diseases (e.g., meningitis and death) in 
immunocompromised individuals, pregnant women and neonates [53-55]. L. monocytogenes has 
the extraordinary capacity to survive within mammalian hosts. It employs a whole set of 
specialized molecules to facilitate adhesion and internalization into the host cells, escape from 
vacuoles, actin-based bacterial motility and cell-to-cell spread without being decimated by the 
host during the process. Many of those bacterial virulence-associated molecules have been 
identified, the most notable of which is the PrfA-regulated virulence genes that cluster on an 
approximately 9.8kb- region of the chromosome, termed the virulence gene cluster (vgc). The 
vgc locus encodes the prfA, plcA, hly, mpl, actA, plcB and 3 other genes ORFx, y and z, which 
are organized in three operons [56] (Fig 2.1A ). The hly encoded listeria hemolysis, listeriolysin 
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O (LLO) is the most essential component for the L. monocytogenes intracellular life cycle. In the 
bacterial infection, L.m are initially phagocytosed by macrophages and hepatocytes and thereby 
enclosed within membrane-bound vacuoles [57]. With the help of phosphatidylinositol-
phospholipase C (PI-PLC, encoded by plcA), LLO disrupts the membrane-bound vacuoles and 
release the engulfed L.m to the cytoplasm. Strains that contain mutated hly gene would be 
trapped and remain inside the vacuoles and become absolutely avirulent [58, 59]. Actin nucleator 
ActA (encoded by actA) promote formation of  actin structures and propel the bacterium 
movement toward the cytoplasmic membrane, where L.m is then enveloped in filopodium-like 
structures and engulfed by adjacent cells in double-layer membrane vacuoles [55]. 
Phosphatidylcholine-phospholipase C (PC-PLC) activated by Mpl (a metalloprotease encoded by 
mpl) works in collaboration with LLO to disrupt the double-layer membrane vacuoles and 
initiate a new infection cycle of L.m [60, 61]. PrfA (encoded by prfA) is a positive regulator that 
is required for the expression of hly and other genes in vgc locus [55, 62]. Besides vgc encoding 
determinants, bacterial surface proteins internalins (e.g., InlA and InlB) also play an important 
role in L.m pathogenesis by facilitating the active entrance of L.m to non-phagocytic cells (e.g., 
epithelial cells) [63]. 
As a facultative intracellular bacterium, L.m infection can induce robust cell-mediated immune 
responses by eliciting both CD8
+
 cytotoxic T-lymphocytes (CTL) and type I CD4
+
 helper T-
lymphocyte (Th1)  responses [64]. This feature makes L.m an attractive antiviral vaccine vector 
that can deliver target viral antigen into intracellular environs to strengthen the host’s CD8+ and 
CD4
+
 T cell responses as well as innate immune response against the virus. Recombinant L.m 
vaccines have been developed for LCMV, murine influenza virus and HIV [51, 65, 66]. 
However, the safety of recombinant L.m remains an important issue, given the possibility of the 
27 
spread of the L.m vector from a recipient to immunocompromised individuals [45]. Over 
replication of L.m vector in such subpopulations can cause severe and life-threatening infections 
[67, 68]. In addition, infection of L.m can also cause undesired CD4
+
 T-cell mediated delayed 
type hypersensitivity (DTH) responses and granulomatous inflammation [69, 70]. Therefore, the 
risk associated with live L.m may significantly hinder the vaccine development of this vector. 
The possibility of using naturally nonpathogenic strains as candidate vaccines has also been 
explored [71, 72]. A previous study showed that the transfer of the whole set of L.m vgc locus 
into a non-pathogenic strain Listeria innocua (L.inn), significantly increased its in vivo survival 
rate in mice and conferred the capability to induce a protective immune response against wild 
type L.m [72]. However, over complementation of a non-pathogenic strain with virulent 
determinants can turn it in to a pathogenic strain and raise safety concerns. Hence, a satisfactory 
balance between attenuation and immunogenicity is the key factor in the clinical development of 
Listeria vaccine vectors. 
The goal of this study is to generate a L.inn vaccine vector by transforming it with the minimal 
amount of L.m virulent determinants that is enough for inducing an effective immune response 
towards expressed viral antigens. To explore this approach, we constructed a shuttle vector pHT-
E2 that can express classical swine fever (CSF) viral antigen E2 in L.inn. At the same time the 
plcA-prfA operon of L.m virulence gene cluster (vgc) was cloned into the pHT-E2 to enhance the 
expression of E2 in L.inn. In further studies we plan to clone additional L.m virulence genes into 
this shuttle vector and evaluate vaccine efficacy of rL.inn carrying different L.m determinants in 
their ability to protect pigs from CSFV challenge.  
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2.2 Materials and Methods  
2.2.1 Bacterial strains. 
Bacteria strains used in this study includes a wild type Listeria innocua Seeliger Serotype 6a 
(ATCC 33090), a recombinant L. monocytogenes strain [72], E. coli One Shot OmniMAX 2 T1 
R chemically competent cells (Life Technology) and E. coli 10-beta chemically competent cells 
(NEB). E. coli strains were grown in Luria-Bertani (LB) broth or on LB agar plates 
supplemented with100 μg/ml ampicillin. Listeria strains were grown in Brain Heart Infusion 
(BHI) Broth (BD 237500) or on BHI agar plates (BD 211065) in presence or absence of 5 μg/ml 
chloramphenicol.  Chloramphenicol was used as a selective antibiotic for growth of L.inn 
harboring the empty or recombinant pHT-01 vector.  
2.2.2 Codon optimization and synthesis of CSF E2 gene  
E2 is an envelope glycoprotein of classical swine fever virus (CSFV). The signal peptide, 
ectodomain and transmembrane region of CSF E2 gene (GenBank: AJ704817) were predicted by 
SignalP 4.1 and PredictProtein online analysis tools. Condon of ectodomain (24aa-364aa) was 
optimized for the preference of L.inn using Codon Usage Database 
(http://www.kazusa.or.jp/codon/) (Condon usage table: Listeria innocua [gbbct]: 3137) and 
codon adaptation tools, Optimizer (http://genomes.urv.es/OPTIMIZER/) and Jcat 
(http://www.jcat.de/). Optimized E2 ectodomain sequence has a percentage content of GC of 
36%, close to the average value of 37% of the L.inn genome. Optimized ectodomain was 
synthesized (GenScript) with modified 5’ terminal BbvCI and a 3’ terminal AvrII enzyme sites 
for future cloning. 
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2.2.3 Construction of pHT01-E2 vector 
An expression vector for heterologous expression of CSFV E2 in L.inn was constructed. A 
Bacillus/E. coli shuttle vector pHT01 (MoBiTec) was used in this study. pHT01 contains 
replication elements from Bacillus subtilis plasmid pBS72 [73] and ColE1 derivative replicon for 
replication in E. coli. A synthesized Multiple Cloning Sites (MCS) with the promoter (P) and 
signal sequences (SS) of the hly gene in it was cloned into the pHT01 vector using SacI and 
XmaI enzyme sites. Synthesized E2 ectodomain was cloned into the MCS in pHT01using BbvCI 
and AvrII enzyme sites right behind the Phly. The recombinant vector, pHT01- E2, was 
chemically transfected into E. coli One Shot OmniMAX 2. Recombinant clones were examined 
for correctness of insertion by PCR with specific primers E2test-F: 
AGGTGGTAACTGGACTTGTG and pHT01test-R: TATCGCCTTGTGGCTTTCTA. 
Recombinant plasmid was purified with QIAprep Spin Miniprep Kit (Qiagen) and verified by 
restriction digests with BbvCI and AvrII.  
2.2.4 Construction of pHT01- VGCpart1-E2 vector 
VGCpart1 was PCR amplified from L. monocytogenes genome DNA by using primer pair 
VGCpart1-F: CACCggtaccCGTACGCGTTCATGAAAATGC (KpnI site was underlined) and 
VGCpart1-R: GTCACTGCATCTCCGTGGTA. VGCpart1a PCR fragment was purified by 
QIAquick Gel Extraction Kit (Qiagen). pHT01- E2 and VGCpart1 fragment were digested with 
KpnI and BstZ17I and then purified with QIAquick PCR Purification Kit (Qiagen). Ligation 
between digested pHT01- E2 and VGCpart1a fragment was carried out using T4 ligase (NEB) 
according to manufacturer's instructions. After overnight incubation at 16°C, the ligation mixture 
was transfected into One Shot OmniMAX 2 competent E. coli. Recombinant clones were 
examined for correctness of insertion by PCR with specific primers M13-F: TGTAAAACGACG 
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GCCAGT and VGCtestP1a-R: TACAGAAACATCGGTTGGCT. Recombinant plasmid was 
purified with QIAprep Spin Miniprep Kit (Qiagen) and confirmed by sequencing of the junction 
between VGCpart1a insert and vector.  
2.2.5 Preparation of electrocompetent L. innocua cells 
L. innocua was made electrocompetent using methods previously described [74]. Briefly, 
overnight cultures of L. innocua, in BHI containing 0.5 M sucrose were diluted (1:100) into fresh 
media (BHI + 0.5 M sucrose) and grown at 37°C with shaking at 250 rpm until reaching an 
OD600 of 0.2. Penicillin G was added to a final concentration of 10 μg /ml and the incubation 
continued for an additional 2 hours. Cells were harvested by centrifugation (8,000×g, 10min, at 
4°C) and washed 3 times in ice-cold washing solution (1 mM HEPES (pH 7.0), 0.5 M sucrose), 
once with equal volume and twice with ½ volumes. Cell pellet was re-suspended in 0.0025 
amount of the same buffer.  
2.2.6 Transformation of L. innocua 
Transformation was performed using 100 μl electrocompetent L. innocua cells and 1μl sterile 
water or 1 μg purified plasmid of pHT-VGCpart1a- E2, pHT- E2 or pHT01. The mixture of 
electrocompetent cells and plasmid were transferred to a 1mm disposable cuvette (Bio-Rad) and 
stored on ice for 5 min. Electroporation was conducted in a Gene Pulser (Bio-Rad) at a field 
strength of 1000V with pulse duration of 5ms. Transformed cells were mixed with 1 ml BHI 
supplemented with 0.5 M sucrose immediately and incubated at 37 °C for one hour. After, the 
transformation mixture was diluted and placed onto BHI plates containing 5 μg/ml 
chloramphenicol (Cm). Plates were incubated overnight at 37°C for 3-4 days to allow the 
recombinant colonies to form. Recombinant colonies were then inoculated to fresh BHI broth 
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containing 5 μg/ml Cm for 1-2 days. Total DNA was extracted from 1.5ml bacterial culture with 
DNeasy Blood & Tissue Kit (Qiagen) and PCR was conducted to determine the transformation 
efficiency. Specific primer pairs used in PCR include 1. E2test-F: 
AGGTGGTAACTGGACTTGTG and pHT01test-R: TATCGCCTTGTGGCTTTCTA (for 
detecting E2 gene); and 2. M13-F: TGTAAAACGACGGCCAGT and VGCtestP1a-R: 
TACAGAAACATCGGTTGGCT (for detecting VGCpart1a). 
2.2.7 SDS-PAGE and western blots 
Recombinant bacteria were grown in BHI supplemented with 5 μg/ml Cm to an optical density at 
600 nm of 1.0. After centrifugation, culture supernatant (3ml) was precipitated with 10% 
trichloroacetic acid, washed twice with acetone, and dissolved in 180 μl of 20 mM Tris-HCL 
(pH 8.0). Bacterial pellets were suspended in 180 μl enzymatic lysis buffer (2 mg/ml lysosome in 
20 mM Tris-HCL, pH 8.0 containing 2 mM sodium EDTA, 1.2% Triton X-100 and 1% protein 
inhibitor cocktail), incubated for 30 min at 37°C and disrupted by ultrasonication on ice. Protein 
extracts normalized to 0.5 ml of original culture were electrophoresed in SDS-% PAGE gel in 
duplicate for staining or for immunoblotting with Precision Plus Protein Kaleidoscope standards 
(Bio-Rad) as molecular weight markers. Proteins were transferred to nitrocellulose membrane 
and probed with a monoclonal anti-E2 antibody (Animal Health & Veterinary Laboratories 
Agency), (diluted 1: 2500 in 1% milk in PBST) overnight at 4°C with gentle rocking. 
Subsequently the membrane was washed twice with PBST, incubated with goat anti-mouse HRP 
secondary antibody 0.8μg/ml in 1% milk in PBST for 1 hour at room temperature and then 
washed thrice with PBST. Finally, the immunoblotting was performed with the ECL reagent 
(Percie) as recommended by the manufacturer. 
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2.3 Results 
2.3.1 Construction of a shuttle vector that can stably maintain foreign genes in Listeria. 
pHT01 is an expression vector that can replicate in both Bacillus and E.coli. The original 
promoter that is used for foreign gene expression in Bacillus in the pHT01 was replaced by a 
new synthesized MCS with promoter (P) and signal sequences (SS) of L.m hly gene in it (Fig. 
2.1).  A synthesized E2 ectodomain was inserted into the BbvCI and AvrII sites right behind the 
hly SS, and the new construct was named pHT- E2 (Fig. 2.1). pBS72 replicon in pHT01 vector 
was isolated from Bacillus subtilis. It is a low-copy replicon using theta-mode replication 
mechanism that can stably maintain large plasmids (~90kb) in Bacillus. The use of pBS72 
replicon in Listeria has not been reported before. To test the replication ability of pHT-E2 in 
L.inn, electroporation was conducted to transformed wild type L.inn with pHT-E2 and the 
resulting strain was named L.inn::e2. pHT-E2 was detected in total DNA extracts purified from 
L.inn::e2 by PCR using specific primers (Fig 2.2). This result suggested that pBS72 replicon can 
work properly in L.inn.  
2.3.2 Cloning of the plcA-prfA operons into the pHT- E2 vector. 
L.m VGC locus consists of three operons, the plcA-prfA operon, the hly operon and the 
lecithinase operon [56]. We planned to clone these three operons separately into the pHT- E2 
vector. In this way, we can evaluate the influence of each operon on the vaccine efficacy of the 
recombinant L.inn vector and identify the best balance between immunogenicity and 
pathogenesis. PrfA encoded by prfA gene in the plcA-prfA operon is a positive regulatory factor 
for most of L.m virulent genes, including hly. Transcription of prfA can be initiated from two 
different premotor region, one in front of the prfA gene and the other one in front of the plcA 
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gene [75]. L.m strain with interrupted prfA gene, expressed barely detectable levels of hly mRNA 
[56]. We expected the presence of plcA-prfA operon can enhance the expression level of E2 gene 
driven by hly promoter in the L.inn. The plcA-prfA operon (VGCpart1) was amplified by PCR 
from purified L.m genome and cloned into the pHT- E2 vector by KpnI and BstZ17I sites. The 
new recombinant vector was referred to pHT- VGCpart1-E2. pHT-VGCpart1-E2 was 
transformed into wild type L.inn by electroporation and the resulting strain was named 
L.inn::vgc1+e2. Both VGCpart1 and E2 were detected in total DNA extracted from recombinant 
L.inn by PCR using specific primers (Fig 2.2).  
2.3.3 Expression of the CSF E2 in recombinant L.inn. 
Listeriolysin O (LLO) encoded by hly gene is a secretory hemolysin in L.monocytogenes. We 
anticipate the expression and secretion under control of the promoter and signal sequences of 
LLO would channel the foreign E2 protein to the host cell cytoplasm for antigen processing and 
presentation. To test the expression and compartmentalization of E2 in L.inn vector, L.inn::e2 
and L.inn::vgc1+e2 were grown under conditions in which the prfA gene and hly promoter is 
maximally expressed (37°C and neutral pH). Proteins in both supernatants and total cell lysates 
of recombinant L.inn cultures were extracted and subjected to immunoblotting test (Fig 2.3). 
Western blot using monoclonal anti-E2 antibodies detected E2 (40kDa) expression in total cell 
lysates of both L.inn::e2 and L.inn::vgc+e2  cultures. Results show that E2 expression level was 
barely detectable in L.inn::e2 cell lysates. This may be the result of the low expression efficiency 
of Phly in the absence of its positive regulatory factor PrfA in L.inn::e2. Unexpectedly, E2 
expression was not detected in supernatants of either L.inn::e2 or L.inn::vgc+e2  cell culture. A 
possible reason for this is that the E2 did not form the correct conformation due to the inability of 
Listeria to form disulfide bonds.  
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2.4 Discussion  
To introduce heterologous genes into Listeria, genes may be carried on plasmids or integrated in 
the listeria genome. Integration-based methods may confer better genetic stability but usually can 
only maintain one copy of the foreign gene in the bacterial genome and these results in low 
expression levels. Plasmids, on the other hand, can maintain higher copies and facilitate an 
increase in antigen expression. pHT01 is a shuttle vector that can replicate in both Bacillus and 
E. coli. It carries an E. coli replicon ColE1 and a theta-mode replication element pBS72 derived 
from natural plasmids in Bacillus subtilis [73]. Natural plasmids using pBS72 or pBS72 derived 
replicons have an average size around 90kb. The vector constructed based on pB72 replicon has 
been proved that it can be stably inherited in B. subtilis and maintain a low copy number, around 
6 units per chromosome [73]. There are other theta-mode replication origins like pAMβ1 isolated 
from Enterococcus faecalis [52, 76] and pIP501 isolated from Streptococcus agalactiae [77, 78] 
that have been used in contracting replicating plasmid in Listeria. However, the pB72 replicon 
that adopts an original initiation mechanism independent of DNA polymerase I has not been used 
in Listeria before [73, 79]. In this study, we constructed a pHT01-based CSFV E2 expression 
vector, pHT-E2. Wild type L.inn was transferred with pHT-E2 by electroporation and E2 gene 
could be detected by PCR in the progeny cells, suggesting that pB72 can work properly in 
Listeria.  
Non-pathogenic L.inn is genetically the closest species to L. monocytogenes in the Listeria genus. 
Comparative genomic studies show that the most notable difference between these two species is 
the lack of vgc locus and certain internalin genes of L.m in the genome of L.inn. Previous studies 
also showed that the transfer of the full-length vgc locus into L.inn significantly increased its in 
vivo survival rate in mice and conferred its ability to induce protective immune responses against 
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wild type L.m [72]. The vgc locus encoding proteins are involved in every stage of L.m 
intracellular life cycles. hly and plcA enable the escape of bacteria from the vacuole; actA 
facilitates the actin-based bacterial motility; plcB facilitate the cell-to-cell spread; and prfA, as a 
transcription enhancer, up-regulated the expression of virulent genes in host. L.inn transferred 
with the entire vgc is capable of escaping from the phagolysosome and surviving inside 
phagocytic cells. This raises the concern that over complementation with virulent determinants 
could lead to over-replication of L.inn vector, especially in immunocompromised hosts. Previous 
studies found that infection with L.m mutants that lack the ability for cell-to-cell spread or to 
multiply in cytosol can also elicit protective immunity by inducing robust expansion of epitope-
specific CD8
+
 T cells [80-82]. Hamilton and colleagues showed that hly deficient L.m that 
expression an additional CD8+ T cell epitope derived from LCMV induced sizable priming of 
epitope-specific CD8
+
 T cells and the development of a functional memory cell population in 
mice after injection and offered protection against challenge with wild-type L.m and LCMV [83]. 
Those studies suggest that an intact intracellular life cycle of listeria vector is not indispensable 
for evoking a desirable immune response. 
Our goal of was to develop a strategy to generate an L.inn vaccine vector by complementing it 
with a minimal number of L.m virulence determinants sufficient to elicit an effective immune 
response against expressed viral antigens. To explore this approach, we planned to clone the 
three operons in L.m vgc separately into the pHT- E2 vector. In this way, we can evaluate the 
influence of each operon on the vaccine efficacy of recombinant L.inn vector and identify the 
best balance between immunogenicity and pathogenesis. The plcA-prfA was the first operon we 
cloned into the pHT-E2 to enhance the expression of E2 in L.inn. In the immunoblotting test, E2 
was detected in the cell lysates of L.inn::e2 but in a lower level than its expression in cell lysates 
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of L.inn::e2. This result suggests that the presence of PrfA can up-regulate the foreign gene 
expression driven by hly promotor. Unexpectedly, the expression of E2, which was supposed to 
be under the control of the secretory signal sequences of LLO, was not detected in supernatants 
of either L.inn::e2 or L.inn::vgc+e2 cell culture. The possible reason for this is that Listeria may 
not be effective in forming disulfide bonds. The E2 ectodomain contains at least four disulfide 
bonds and they are key structural elements that stabilize the native conformation of E2 [84, 85]. 
The lack the correct disulfide bonds may reduce the solubility and secretion of E2 in L.inn. 
However, a previous study suggests that the compartmentalization of carried antigen in Listeria 
vector would not affect the antigen presentation by MHC class I pathway to prime CD8
+
 T cells 
[86]. In future studies, we plan to clone additional L.m virulence genes into the shuttle vector to 
increase immunogenicity of this recombinant L.inn, and test the vaccine efficacy of rL.inn 
carrying different L.m determinants in their ability to protect pigs from CSFV.  
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2.5 Figures and Tables 
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Figure 2.1 Construction of the pHT-E2 shuttle vector and organization of L.m vgc locus. (A) 
L.m VGC locus consists of three operons, the plcA-prfA operon, the hly operon and the 
lecithinase operon (modified from Portnoy, D.A., 1992) [56]. (B) Synthesized multiple cloning 
site (MCS) with hly promoter (Phly) and signal sequence (hly SS) in it. (C) Map of pHT-E2 
vector. ColE1, E. coli replication origin; repA, major replication element in Bacillus plasmids 
pBS72; E2, ectodomain of CSFV E2 gene; Phly-SS, promoter and signal sequences of L.m hly 
gene. Map was developed using Addgene (www.addgene.org). 
 
 
 
Figure 2.2 PCR confirmation of recombinant L.inn strains, L.inn::e2 and L.inn::vgc1+e2 . 
M = Quick-Load 1 kb Extend DNA Ladder (NEB); 1-4 = amplification of the E2 gene (target 
band: 906bp) from L.inn::e2, L.inn::vgc1+e2, plasmid pHT01-Part1a-E2 (positive control), 
L.inn transformed with pHT01 vector (negative control), respectively. 5-7 = amplification of 
VGCpart1a (target band: 605bp) from L.inn::vgc1+e2, plasmid pHT01-Part1a-E2 (positive 
control),  L.inn transformed with pHT01 vector (negative control), respectively. 
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Figure 2.3 Western blot for the recombinant L.inn strains. Proteins in both supernatants and 
total cell lysates of recombinant L.inn cultures were extracted and subjected to immunoblotting 
test. Proteins were probed with a monoclonal anti-E2 antibody (WH211). (A) 1, 3 = cell lysates 
of L.inn transformed with pHT01 vector (negative control) and L.inn::vgc1+e2; 2,4 = 
supernatant from L.inn transformed with pHT01 vector (negative control) and L.inn::vgc1+e2, 
respectively;  (B) 5, 7 = cell lysates of L.inn::vgc1+e2 and L.inn::e2; 6,8 = supernatant from 
L.inn::vgc1+e2 and L.inn::e2, respectively. 
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